NCT06231368View on ClinicalTrials.gov

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 4, 2024

Primary Completion Date

November 18, 2024

Study Completion Date

August 31, 2025

Conditions
Autoimmune Hemolytic AnemiaAutologous CD19 CAR-TFailure of Three or More Lines of Therapy
Interventions
BIOLOGICAL

CNCT19 CAR-T cell therapy

CNCT19 was a second-generation CAR T-cell with scFv derived from clone HI19α and 4-1BB/CD3-ζ costimulatory domain.

Trial Locations (1)

Unknown

Regenerative Medicine Center, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER